Mineralys Therapeutics, Inc. (MLYS) annual income statement — 6-year revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 21K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -21K | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - |
| Operating Expenses | 171.48M | 170.6M | 192.4M | 84.66M | 31.48M | 18.73M | 2.94M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 53M | 38.59M | 23.82M | 14.3M | 5.23M | 2.42M | 532K |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 118.5M | 132.01M | 168.58M | 70.36M | 26.25M | 16.31M | 2.41M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -171.5M | -170.6M | -192.4M | -84.66M | -31.48M | -18.73M | -2.94M |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 11.33% | -127.27% | -168.93% | -68.11% | -536.26% | - |
| EBITDA | -171.45M | -170.54M | -192.36M | -84.66M | -31.48M | -19.38M | -3.31M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | 14.89% | 11.34% | -127.22% | -168.93% | -62.42% | -485.35% | - |
| D&A (Non-Cash Add-back) | 50K | 59K | 43K | 0 | 0 | 0 | 0 |
| EBIT | -167.3M | -170.6M | -192.4M | -84.66M | -31.48M | -19.38M | -3.31M |
| Net Interest Income | 19.71M | 15.95M | 14.59M | 12.76M | 0 | -27K | -115K |
| Interest Income | 19.71M | 15.95M | 14.59M | 12.76M | 1.68M | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 1.68M | 27K | 115K |
| Other Income/Expense | 19.72M | 15.95M | 14.59M | 12.76M | 1.68M | -683K | -483K |
| Pretax Income | -151.78M | -154.65M | -177.81M | -71.9M | -29.8M | -19.41M | -3.43M |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -151.78M | -154.65M | -177.81M | -71.9M | -29.8M | -19.41M | -3.43M |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | 19.49% | 13.02% | -147.31% | -141.28% | -53.54% | -466.49% | - |
| Net Income (Continuing) | -151.78M | -154.65M | -177.81M | -71.9M | -29.8M | -19.41M | -3.43M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.83 | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 |
| EPS Growth % | 45.04% | 37.43% | -83.92% | 65.51% | -48.33% | -425.68% | - |
| EPS (Basic) | - | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 |
| Diluted Shares Outstanding | 82.83M | 67.66M | 48.54M | 36.19M | 5.17M | 4.98M | 4.63M |
| Basic Shares Outstanding | 82.83M | 67.66M | 48.54M | 36.19M | 5.17M | 4.98M | 4.63M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying MLYS stock.
For fiscal year 2025, Mineralys Therapeutics, Inc. (MLYS) reported total revenue of $0.0M.
Mineralys Therapeutics, Inc. (MLYS) reported a net loss of $154.7M for the fiscal year ending 2025.